PharmaCorp Rx Inc (PCRX) Fair Value & Analysis
Healthcare · CA · Market cap C$87.0M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price −2.0% over the past month.
Price vs Fair Value (12 months)
12‑month range C$0.4080 – C$0.5508 · fair‑value band C$0.6700 – C$1.12 · the C$0.5100 price screens below the C$0.8900 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
PharmaCorp Rx Inc (PCRX) currently trades at C$0.5100, while our model-based Fair Value estimate is C$0.8900 — implying the stock looks roughly 74.5% undervalued today. We read business quality at 90/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, PharmaCorp Rx Inc generated revenue of C$24.1M at a net margin of -6.7%. Revenue grew 79.4% year over year. It earns a return on equity of -3.7%. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PharmaCorp Rx Inc. operates retail pharmacies under the PharmaChoice name in Canada. The company offers prescription services; front-of-store retail, such as convenience goods, over-the-counter medications, health products, and wellness items; custom compounding; specialized consultations; and lifestyle programs. PharmaCorp Rx Inc. was incorporated in 2021 and is headquartered in Saskatoon, Canada.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
PharmaCorp Rx Inc reported revenue of C$20.9M in FY2025 versus C$0 in FY2022. Reported net income was −C$1.4M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| JD Health International Inc JDHIY | $5.33 | $7.09 | +33% |
| Alibaba Health Information Technology Limited ALBBY | $8.56 | $6.91 | -19% |
| Raia Drogasil S.A RADL3 | R$16.79 | R$20.39 | +21% |
| Yifeng Pharmacy Chain Co 603939 | ¥19.75 | ¥29.07 | +47% |
| Clicks Group CLCGY | $28.55 | $41.54 | +45% |
| Sugi Holdings SGIPF | $16.29 | $64.34 | +295% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PharmaCorp Rx Inc (PCRX) undervalued?
What is the fair value of PCRX?
What is the quality score of PCRX?
What is the revenue of PharmaCorp Rx Inc (PCRX)?
What is the net profit margin of PCRX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.